Tumor necrosis factor alpha (TNF) inhibitors have had a significant impact in medicine since the approval of the first drug of its class by the US FDA in 1998. New clinical data and indications have emerged for TNF inhibitors in recent years. Currently, four TNF inhibitors have been approved by the US FDA for dermatology, two of which include US FDA-approved pediatric use. In particular, growing evidence supports the use of etanercept and adalimumab as attractive therapies for pediatric psoriasis. Data for use of etanercept in treating toxic epidermal necrolysis and either etanercept or infliximab for Kawasaki disease is expanding. In addition, there have been clinical reports on the use of TNF inhibitors to treat a variety of other pediatric dermatologic conditions. To help clinicians keep pace with the new data provided by many pediatric dermatology studies involving TNF inhibitors, this review provides an overview of the use of TNF inhibitors in the treatment of pediatric plaque psoriasis, hidradenitis suppurativa, atopic dermatitis, pyoderma gangrenosum, toxic epidermal necrolysis, and Kawasaki disease. For TNF inhibitors with little data in the pediatric population, data on adult use is discussed. Furthermore, the review summarizes available clinical data on efficacy, safety, and tolerability of agents currently available.

中文翻译：

---

TNFα抑制剂在治疗小儿皮肤病中的应用

自 1998 年美国 FDA 批准第一个同类药物以来，肿瘤坏死因子α (TNF) 抑制剂在医学上产生了重大影响。近年来，TNF 抑制剂出现了新的临床数据和适应症。目前，美国 FDA 已批准四种 TNF 抑制剂用于皮肤病学，其中两种包括美国 FDA 批准的儿科用途。特别是，越来越多的证据支持使用依那西普和阿达木单抗作为治疗小儿银屑病的有吸引力的疗法。使用依那西普治疗中毒性表皮坏死松解症以及使用依那西普或英夫利昔单抗治疗川崎病的数据正在扩大。此外，已有关于使用 TNF 抑制剂治疗各种其他儿科皮肤病的临床报告。为了帮助临床医生跟上许多涉及 TNF 抑制剂的儿科皮肤病学研究提供的新数据，本综述概述了 TNF 抑制剂在治疗儿科斑块状银屑病、化脓性汗腺炎、特应性皮炎、坏疽性脓皮病、中毒性表皮坏死松解症中的应用，和川崎病。对于在儿科人群中数据很少的 TNF 抑制剂，讨论了成人使用数据。此外，该评价总结了目前可用药物的有效性、安全性和耐受性的可用临床数据。对于在儿科人群中数据很少的 TNF 抑制剂，讨论了成人使用数据。此外，该评价总结了目前可用药物的有效性、安全性和耐受性的可用临床数据。对于在儿科人群中数据很少的 TNF 抑制剂，讨论了成人使用数据。此外，该评价总结了目前可用药物的有效性、安全性和耐受性的可用临床数据。